Onconetix (NASDAQ:ONCO) Major Shareholder Purchases $25,284.28 in Stock

Onconetix, Inc. (NASDAQ:ONCO) major shareholder Financial Lp Hrt bought 34,636 shares of Onconetix stock in a transaction on Friday, April 17th. The shares were acquired at an average price of $0.73 per share, for a total transaction of $25,284.28. Following the completion of the acquisition, the insider owned 177,821 shares of the company’s stock, valued at approximately $129,809.33. This represents a 24.19% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Tuesday, April 21st, Financial Lp Hrt sold 49,710 shares of Onconetix stock. The stock was sold at an average price of $0.69, for a total value of $34,299.90.
• On Thursday, April 16th, Financial Lp Hrt sold 53,867 shares of Onconetix stock. The stock was sold at an average price of $0.73, for a total value of $39,322.91.
• On Monday, April 20th, Financial Lp Hrt sold 94,462 shares of Onconetix stock. The stock was sold at an average price of $0.75, for a total value of $70,846.50.
• On Wednesday, April 15th, Financial Lp Hrt bought 92,554 shares of Onconetix stock. The shares were acquired at an average price of $0.76 per share, for a total transaction of $70,341.04.
• On Tuesday, April 14th, Financial Lp Hrt bought 74,350 shares of Onconetix stock. The shares were acquired at an average price of $0.77 per share, for a total transaction of $57,249.50.

Onconetix Trading Down 7.9%

ONCO stock opened at $0.67 on Friday. The business’s 50-day moving average price is $2.35 and its two-hundred day moving average price is $8.40. The firm has a market cap of $442,200.00, a PE ratio of 0.00 and a beta of 3.63. Onconetix, Inc. has a 1-year low of $0.65 and a 1-year high of $74.29.

Institutional Trading of Onconetix

An institutional investor recently bought a new position in Onconetix stock. Citadel Advisors LLC purchased a new stake in Onconetix, Inc. (NASDAQ:ONCO) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 15,633 shares of the company’s stock, valued at approximately $49,000. Citadel Advisors LLC owned 1.00% of Onconetix at the end of the most recent reporting period. Institutional investors own 23.89% of the company’s stock.

Onconetix Company Profile

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.